Skip to main
OCS
OCS logo

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding AG has demonstrated strong progress in its clinical trials, particularly with OCS-05 in acute optic neuritis (AON), where the Phase 2 ACUITY trial showed statistically significant improvements in low contrast visual acuity, suggesting a robust pipeline and heightened investor confidence. The anticipated timelines for the upcoming PIONEER studies, with initiation dates in late 2025 to mid-2026, reflect the company's commitment to rapid development and effective communication with the FDA. Additionally, positive responder rates in the Phase 2b RELIEF study for OCS-01 highlight the potential for future success, reinforcing the positive outlook on the company's growth trajectory and market positioning.

Bears say

Oculis Holding AG faces significant challenges that contribute to a negative outlook, including potential delays in clinical development and regulatory approvals, which may result in prolonged development timelines and escalated costs. The company reported a net loss of CHF 16.9 million in 3Q25, raising concerns about its financial sustainability amid competitive pressures from existing and emerging therapies in the eye care market. Furthermore, the risk of inadequate efficacy or safety demonstrated by its development candidates OCS-01, OCS-02, and OCS-05 in clinical trials could severely impact the company's future viability and market positioning.

OCS has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 6 analysts, OCS has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.